Document:

EX-10.11.2

 Exhibit 10.11.2 
 SECOND AMENDMENT TO LEASE 
 THIS SECOND
AMENDMENT TO LEASE (this “Second Amendment”) is made as of this 10th day of September, 2012, by and between ARE-SD REGION NO. 18, LLC, a Delaware limited liability company (“Landlord”), and BIOCEPT, INC., a California corporation
(“Tenant”). 
 RECITALS 

A.        Landlord and Tenant are now parties to that certain Lease dated as
of March 31, 2004, as amended by that certain First Amendment to Lease dated as of November 1, 2011 (as amended, the “Lease”). Pursuant to the Lease, Tenant leases certain premises consisting of approximately 38,369 square
feet of Rentable Area (“Premises”) in the building located at 5810 Nancy Ridge Drive, San Diego, California. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease. 

B.        Tenant has requested and Landlord has agreed, subject to the terms
and conditions set forth below, to among other things, defer the full Basic Annual Rent and management fees payable by Tenant under the Lease to Landlord and 50% of the Operating Expenses payable by Tenant under the Lease to Landlord for the period
commencing on September 1, 2012, through November 30, 2012, in the amount of $272,137.89 (“Deferred Rents”). 
 C.        Concurrently with this Second Amendment, in consideration of the Landlord entering into this Second Amendment, Landlord and Tenant are entering into
that certain Warrant to Purchase Preferred Stock dated of even date herewith (“Warrant”). 

NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the
mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: 

 

	1.	 Basic Annual Rent and Operating Expenses.  Notwithstanding anything to the contrary contained in the Lease, for the period
commencing on September 1, 2012, through November 30, 2012 (“Deferral Period”), Tenant shall not be required to pay Basic Annual Rent or management fees for the Premises but Tenant shall be required to pay Operating
Expenses under the Lease to Landlord in the amount of $10,882.09 per month (“Deferral Period Operating Expenses”) during the Deferral Period. Notwithstanding the foregoing, Tenant shall be required to pay for any separately metered
Utilities or services furnished to Tenant or the Premises during the Deferral Period in accordance with Section 16 of the Lease. Tenant shall resume paying full Basic Annual Rent, and Operating Expenses as provided under the Lease on
December 1, 2012. If Tenant enters into one or more sublease agreements with an unaffiliated third party (“Subtenant”) in compliance with the provisions of the Lease for all or any portion of the Premises, any sublease rent or
other payments payable by Subtenant under the sublease (“Pass-Through Amounts”) shall be passed through by Tenant directly to Landlord. During the Deferral Period, (i) Tenant shall continue to pay the full Deferral Period
Operating Expenses on a monthly basis, and (ii) Pass-Through Amounts actually delivered by Tenant to Landlord, if any, shall be applied against Deferred Rents. Following the Deferral Period, Pass-Through Amounts actually delivered by Tenant to
Landlord shall be applied against Basic Annual Rent and Additional Rent payable by Tenant under the Lease. 

 Tenant shall, on or before December 21, 2012, pay to Landlord the sum of $276,952.69 (which is equal to the full amount of the Deferred Rents, together with accrued interest of 8% per annum on the
Deferred Rents) less any Pass-Through Amounts actually paid by Tenant to Landlord during the Deferral Period applicable to Deferred Rents. 

  

			
		  	 

 1 

 In consideration of Landlord’s agreement to enter into this Second
Amendment, as of the date of this Second Amendment, the Deferred Rents (and the accrued interest thereon through December 21, 2012) shall be deemed fully earned by Landlord and shall be paid to Landlord even if the Lease terminates for any
reason at any time (including, without limitation, during the Deferral Period). 
  

	2.	 Default.    In addition to the events of default listed in Section 24.4 of the Lease, a default by Tenant
under the Warrant shall constitute a default under the Lease. 

  

	3.	 Brokers.    Landlord and Tenant each represent that they have had no dealings with any real estate broker, finder or
other person, with respect to this Second Amendment in any manner. Landlord and Tenant agree to indemnify and hold each other harmless from and against any claim or demand of any other broker for any brokerage commission or other fees, and all
costs, claims, expenses and liabilities in connection therewith (including, without limitation, attorneys’ fees, disbursements and actual costs). 

 

	4.	 Miscellaneous. 

 (a)        This Second Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and
contemporaneous oral and written agreements and discussions with respect to the subject matter hereof. This Second Amendment may be amended only by an agreement in writing, signed by the parties hereto. 

(b)        This Second Amendment is binding upon and shall inure to the
benefit of the parties hereto, and their respective assigns, heirs, and successors in interest. 

(c)        This Second Amendment may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the
signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Second Amendment attached thereto. 

(d)        Except as amended and/or modified by this Second Amendment, the
Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Second Amendment. In the event of any conflict between the provisions of this Second Amendment and the
provisions of the Lease, the provisions of this Second Amendment shall prevail. Whether or not specifically amended by this Second Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to
the purpose and intent of this Second Amendment. 
 [Signatures are on the next page] 

  

			
		  	 

 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Second
Amendment as of the day and year first above written. 
  

			
	TENANT:
	
	 BIOCEPT, INC.,
 a
California corporation

		
	By:	 	 /s/ William Kachioff

	Its:	 	Chief Financial Officer

  

			
	LANDLORD:
	
	 ARE-SD REGION NO. 18, LLC,
 a Delaware limited liability corporation

		
	By:	 	ALEXANDRIA REAL ESTATE EQUITIES, L.P.,
		 	a Delaware limited partnership, managing member

  

			
	By:	 	ARE-QRS CORP.,
		 	a Maryland corporation,
general partner

  

			
	By:	 	 /s/ Gary Dean

	Its:	 	 Gary Dean

		 	 VP - RE Legal Affairs

  

  

			
		  	 

 3EX-10.11.3

 Exhibit 10.11.3 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS
WARRANT IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AGREEMENT BY AND BETWEEN THE HOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

BIOCEPT, INC. 
 WARRANT TO PURCHASE PREFERRED STOCK 
  

			
	No. PSW-52	  	Sept 10, 2012

  

THIS CERTIFIES THAT, for value received, ARE-SD
REGION NO. 18, LLC, a Delaware limited liability corporation or its assigns (collectively, the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from BIOCEPT,
INC., a California corporation (the “Company”), up to such number and series of fully paid and nonassessable shares of Preferred Stock (as defined below) of the Company as set forth herein, during the
Exercise Period (as defined below). 
 This Warrant is issued pursuant to the Second Amendment to Lease, dated
Sept 10, 2012, among the Company and the Holder (the “Agreement”). 

1.        DEFINITIONS.  As used
herein, the following terms shall have the following respective meanings: 

  (a)        “Exercise Period” shall
mean the period commencing on the date hereof and ending seven (7) years thereafter, unless sooner terminated as provided below. 
   (b)        “Exercise Price” shall mean (a) if the Company has not closed a Qualifying Financing, $0.60 and
(b) if the Company has closed a Qualifying Financing, the price per share at which the Company sells its Preferred Stock in such Qualifying Financing. 
   (c)        “Exercise Shares” shall mean (a) if the Company has not closed a Qualifying Financing, the Company’s
Series A Preferred Stock and (b) if the Company has closed a Qualifying Financing, the Company’s Preferred Stock sold in such Qualifying Financing. 
   (d)        “Preferred Stock” means shares of the preferred stock of the Company. 

  (e)        “Qualifying Financing” means the
closing of an equity financing following the date hereof involving the sale by the Company of its Preferred Stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds 

  (f)        “Warrant Coverage Amount”
shall be $40,000. 

2.        NUMBER OF
SHARES.  The number of Exercise Shares for up to which this Warrant may be exercisable shall be determined by dividing the Warrant Coverage Amount by the Exercise Price, and rounding down to the nearest
whole share. 
 3.        EXERCISE OF
WARRANT.  The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth on the
signature page hereto (or at such other address as it may designate by notice in writing to the Holder): 

  (a)        An executed Notice of Exercise in the form
attached hereto; 
   (b)        Payment of the
Exercise Price either (i) in cash or by check, (ii) by cancellation of indebtedness, or (iii) any combination thereof; and 
   (c)        This Warrant. 
 Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder,
if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this
Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except
that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the
stock transfer books are open. 
 Holder, in lieu of exercising this Warrant by the payment of the Exercise
Price described above, may elect, at any time on or before the expiration of the Exercise Period, to surrender this Warrant and receive that number of shares of Preferred Stock computed using the following formula: 

Where: X        =        the number of
shares of Preferred Stock to be issued to Holder. 

    Y        =       
 the number of shares of Preferred Stock that Holder would otherwise have been entitled to purchase hereunder (or such lesser number of shares as Holder may designate in the case of a partial exercise of this Warrant). 

    A        =       
 the Per Share Price (as defined below) at the time the net issuance election under this Section 3 is made. 

  
 2. 

    B        =      
  the Exercise Price then in effect. 
 Election to “net exercise” may be made by delivering
a signed form of subscription to Company via facsimile, to be followed by delivery of this Warrant. Notwithstanding anything to the contrary contained in this Warrant, if as of the close of business on the last business day preceding the expiration
of the Exercise Period this Warrant remains unexercised as to all or a portion of the shares of Preferred Stock purchasable hereunder, then effective as 9:00 a.m. (Pacific time) on such expiration Date, Holder shall be deemed, automatically and
without need for notice to Company, to have elected to “net exercise” this Warrant in full using the above formula, provided that the application of such formula as of such expiration date yields a positive number for “X”.
“Per Share Price” means: (i) If this Warrant is exercised on the date of Company’s initial public offering of Common Stock, and if Company’s registration statement relating to such public offering has been declared effective
by the Securities and Exchange Commission, then the Per Share Price shall be the initial “Price to Public” of the Common Stock specified in the final prospectus with respect to the offering; (ii) If this Warrant is exercised after,
and not on the date of Company’s initial public offering of Common Stock, and if Company’s Common Stock is traded on a securities exchange or actively traded over-the-counter: (a) If Company’s Common Stock is traded on a
securities exchange, the Per Share Price shall be deemed to be the closing price of Company’s Common Stock as quoted on any exchange, as published on Yahoo! Finance (or a successor thereto or equivalent publisher) for the trading day
immediately prior to the date of Holder’s election hereunder and (b) If Company’s Common Stock is actively traded over-the-counter, the Per Share Price shall be deemed to be the closing bid or sales price, whichever is applicable, of
Company’s Common Stock for the trading day immediately prior to the date of Holder’s election hereunder; (iii) If neither (i) nor (ii) is applicable, the Per Share Price shall be determined in good faith by the Board of
Directors of Company based on relevant facts and circumstances at the time of the net exercise. 

4.      COVENANTS OF THE
COMPANY. 
 4.1        Covenants as to Exercise
Shares.  The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and
free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a
sufficient number of shares to provide for the exercise of the rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares is not sufficient to permit exercise of this Warrant, the
Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares to such number of shares as shall be sufficient for such purposes. The Company shall take all action necessary
to cause the Exercise Shares to be included as “Registrable Securities” pursuant to that certain [Investor Rights Agreement], as subsequently amended (the “Rights Agreement”) and to have the Holder become a party to the Rights
Agreement. 
 4.2        No Impairment.  Except and to
the extent as waived or consented to by the Holder, the Company will not, by amendment of its Amended and Restated Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger,

  
 3. 

 
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the
Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect the exercise rights of the Holder against
impairment. 
 5.        ADJUSTMENT OF
EXERCISE PRICE.  In the event of changes in the outstanding Preferred Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or
exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on
exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event
requiring adjustment; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 8 below. The form of this Warrant need not be
changed because of any adjustment in the number of Exercise Shares subject to this Warrant. 

6.        ADJUSTMENTS FOR
DILUTING ISSUANCES.  The Exercise Price and the number of Exercise Shares issuable upon exercise of this Warrant or, if the Exercise Shares are Preferred Stock, the number of shares of
common stock issuable upon conversion of the Exercise Shares, shall be subject to adjustment, from time to time in the manner set forth in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time, as if the
Exercise Shares were issued and outstanding on and as of the date of any such required adjustment. Any adjustment to the conversion rate of the Exercise Shares issuable upon the exercise of this Warrant effected prior to any exercise of this Warrant
shall apply to any Exercise Shares thereafter issued pursuant to the terms hereof. 

7.        FRACTIONAL
SHARES.  No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this
Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of
issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

8.        EARLY
TERMINATION.  In the event of an Asset Transfer or Acquisition (as defined in the Company’s Amended and Restated Articles of Incorporation, as amended) (other than a merger solely to effect a
reincorporation of the Company into another state), the Company shall provide to the Holder 20 days advance written notice of such event, and this Warrant shall terminate unless exercised prior to the date such transaction is consummated.

 9.        MARKET
STAND-OFF AGREEMENT.  Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar
transaction with the same economic effect as a sale with respect to, any Common Stock (or other securities) of the Company held by such Holder, for a period of time specified by the managing 

  
 4. 

 
underwriter(s) not to exceed 180 days following the effective date of a registration statement of the Company filed under the Securities Act in connection with the Company’s initial public
offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or
similar rule or regulation). Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further
effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. Each Holder agrees that any transferee of Common
Stock (or other securities) shall be bound by this Section 9. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9 and shall have the right, power and authority to enforce the provisions
hereof as though they were a party hereto. 

10.        No SHAREHOLDER
RIGHTS.  This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company. 

11.        TRANSFER OF
WARRANT.  Subject to applicable laws and the restrictions on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized
attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

12.        LOST, STOLEN,
MUTILATED OR DESTROYED WARRANT.  If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may
reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an
original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

13.        NOTICES,
ETC.  All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed
telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one
day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company and the Holder at the address set forth on the signature page
hereto, or at such other address as the Company or Holder may designate by 10 days advance written notice to the other party hereto. 
 14.        ACCEPTANCE.  Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of
the terms and conditions contained herein. 

15.        COUNTERPARTS.  This
Warrant may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 5. 

16.        GOVERNING
LAW.  This Warrant shall be governed by, and construed and enforced in accordance with, the laws of the State of California, applied to agreements between California residents, made to be performed
entirely within the State of California, without giving effect to conflicts of law principles. 

17.        AMENDMENT;
WAIVER.  Any term of this Warrant may be amended or waived with the written consent of (i) the Company and (ii) the Holder. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK] 

  
 6. 

 IN WITNESS
WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of the date set forth above. 

 

			
	BIOCEPT, INC.
		
	By:	 	 /s/ William Kachioff

 
			
		
	Name:	 	 William Kachioff

 
			
		
	Title:	 	CFO
	
	 Address: 5810 Nancy Ridge Drive
                San Diego, California 92121

 Acknowledged and accepted: 
 ARE-SD Region No. 1D, LLC 

					
			
	 By: Alexandria Real Estate Equities, L.P..
	 		  	
			
	        By: ARE-QRS Corp.
	 		  	
			
	              By: /s/ Gary Dean	 		  	
	         GARY DEAN
	 		  	
	 VP-RE LEGAL AFFAIRS
	 		  	

  

							
	Address:	 	 385 E. Colorado Blvd. Suite #299
	 		  	
				
		 	 Pasadena CA 91101
	 		  	

  

[SIGNATURE PAGE TO WARRANT] 

 NOTICE OF EXERCISE 
 TO: BIOCEPT, INC. 

(1)        The undersigned hereby elects to purchase
             Exercise Shares of Biocept, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise
price in full, together with all applicable transfer taxes, if any. 

(2)        Please issue a certificate or certificates representing said
Exercise Shares in the name of the undersigned or in such other name as is specified below: 
  

 
 (Name)

  
  

 
  

(Address) 
 (3)        The undersigned represents that (i) the aforesaid Exercise Shares are being acquired for the account of the undersigned for investment and
not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and
financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of this type and
has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that
the Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of
the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely
unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act
unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company
and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid Exercise Shares unless and until there is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to
the Company, stating that such registration is not required. 
  

					
	 	 		  	  

	 (Date)
	 		  	(Signature)
		 		  	  

		 		  	(Print name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this
form to purchase shares.) 
 FOR VALUE
RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  

			
	Name:	  	 

 (Please Print) 
  

			
	Address:	  	 

 (Please Print) 
 Dated:                     , 20     

 

					
	 Holder’s

Signature:
	  	 	  	

  

					
	 Holder’s

Address:
	  	 	  	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]